



IMHA: When Blood is thinner than water

Stephanie Sorrell BVetMed(Hons) MANZCVS
DipECVIM-CA MRCVS

16th November 2023

IDEXX

Disclosure

- IDEXX Employee


The information contained herein is intended to provide general guidance only. As with any diagnosis or treatment, you should use clinical discretion with each patient based on a complete evaluation of the patient, including history, physical presentation, and complete laboratory data. With respect to any drug therapy or monitoring program, you should refer to product inserts for a complete description of dosages, indications, interactions, and cautions. Diagnosis and treatment decisions are the ultimate responsibility of the primary care veterinarian.



Agenda


Objective

1. Pathophysiology
2. Diagnosis
3. Treatment
4. Case studies
5. Q&A




Pathophysiology

- Immune mediated haemolytic anaemia is due to antibody mediated destruction of red blood cells.
- Canine IMHA is most often primary, i.e, idiopathic.
 - Immune mediated dysregulation
 - Antibody production against unaltered red blood cells
 - No underlying disease identified
- Feline IMHA is most often secondary.




created from biorender.com

Pathophysiology



Pathophysiology of IMHA



created from
biorender.com

Secondary causes for IMHA

Infectious

- + Haemobartonellosis
- + Salmonellosis
- + *Anaplasma phagocytophilum*
- + *Babesia*
- + Feline Infectious Peritonitis

Neoplastic

- + Lymphoma
- + Leukaemia
- + Bronchoalveolar carcinoma
- + Mast cell tumour
- + Splenic haemangiosarcoma

Inflammatory

- + Pancreatitis
- + Prostatitis
- + Systemic lupus erythematosus

Drugs/Toxins

- + Cephalosporins
- + Griseofulvin
- + Methimazole
- + Levamisole

Garden OA, Kidd L, Mexas AM, et al. ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. J Vet Intern Med. 2019;33:313–334. <https://doi.org/10.1111/jvim.15441> 334GARDENET AL.

Diagnosis

- Can be relatively straightforward
- Strong regenerative anaemia expected
- Positive In Saline Agglutination/Coombs expected


BUT **30%** dogs present with non-regenerative anaemia

Takes **3-5 d** days for regenerative response to be seen so care with acute cases




Blood smear assessment


- + Signs of regeneration
 - + Anisocytosis
 - + Polychromasia
- + Spherocytes (not commonly seen in cats)
- + May see ghost cells
- + May see agglutination




Blood smear assessment



Blood smear assessment



Blood smear assessment




Assessing regeneration

- + Reticulocyte count assessed using new methylene blue stain
- + Absolute reticulocyte count ($\times 10^9/L$) = observed reticulocyte count (%) x total red blood cell count ($\times 10^{12}/L$) x10
- + In dogs, an absolute reticulocyte count $>60 \times 10^9/L$ is consistent with a regenerative anaemia and in cats, and absolute reticulocyte count $>50 \times 10^9/L$ is consistent with a regenerative anaemia.



Blood smear assessment – New Methylene Blue



Other testing

Serum biochemistry

- + Expect TP to be normal
- + May see hyperbilirubinaemia
- + May see haemoglobinaemia

Urinalysis

- + May see hyperbilirubinaemia
- + May see haemoglobinuria



Infectious disease testing and imaging

- + FIV/FeLV in cats
- + *Mycoplasma* testing in cats
- + 4Dx/*Babesia* PCR in dogs with travel history
- + Thoracic and abdominal imaging to rule out secondary causes.

Imaging

- + Previous study documenting utility of thoracic radiographs and abdominal ultrasound in dogs with IMHA
 - + in 38 out of 50 dogs, the same clinical evaluation and assessment would have been performed without thoracic radiographs.
 - + In 32 out of 64 dogs, the same clinical evaluation and assessment would have been performed without abdominal ultrasound.
- + The results indicate that thoracic radiographs and abdominal ultrasound are of variable utility

Andres M, Hostnik E, Green E, Langston C, Parker VJ, Gilor C, Rudinsky AJ. Diagnostic utility of thoracic radiographs and abdominal ultrasound in canine immune-mediated hemolytic anemia. *Can Vet J.* 2019 Oct;60(10):1065-1071. PMID: 31597991; PMCID: PMC6741823.

Treatment for Primary IMHA

- + For severely affected patients, a blood transfusion can be lifesaving.
- + No specific PCV at which a transfusion should be considered
- + Pet Blood Bank can supply canine packed red blood cells, however whole blood from in clinic donor dogs can also be considered.
- + For cats there is no UK blood bank and as such we generally rely on in clinic donors.

Xenotransfusion

- + Previous study documenting outcome in forty-nine cats who underwent xenotransfusion
- + Six cats (12%) had febrile non-haemolytic transfusion reactions.
- + Ten cats (20%) died or were euthanased within 24 hours of xenotransfusion.
- + A delayed haemolytic transfusion reaction occurred in 25 of 39 (64%)
- + Of the 18 cats alive at 1 week after discharge, 15 (83%) were still alive at a median of 173 days after xenotransfusion.

Le Gal A, Thomas EK, Humm KR. Xenotransfusion of canine blood to cats: a review of 49 cases and their outcome. *J Small Anim Pract.* 2020 Mar;61(3):156-162. doi: 10.1111/jsap.13096. Epub 2019 Dec 22. PMID: 31867733.

Canine transfusion calculator

Dogs Weight (KG):

Dogs PCV (%):

Desired PCV (%):

Desired PCV increase (%)

if PCV is unknown

Select the results you would like to see:

- Packed Red Blood Cells
- Plasma (Fresh Frozen Plasma or Frozen Plasma and Cryo-Supernatant)
- Cryo-Precipitate
- Whole Blood

<https://www.petbloodbankuk.org/vet-professionals/i-need-advice/canine-transfusion-calculator/>

Feline Formulae

- + Previous study investigate five formulae to predict post transfusion PCV in cats
- + PCV % increase = volume of blood transfused in ml/2 × bodyweight in kg performed best overall and is easy to calculate
- + However, no single formula was highly accurate at predicting the PCV increase after whole blood transfusion in cats

Reed N, Espadas I, Lalor SM, Kisielewicz C. Assessment of five formulae to predict post-transfusion packed cell volume in cats. *J Feline Med Surg*. 2014 Aug;16(8):651-6. doi: 10.1177/1098612X13517254. Epub 2014 Jan 6. PMID: 24393778.

Options for treatment

- + Steroid
- + Cyclosporin
- + Mycophenolate mofetil
- + Azathioprine NEVER IN CATS



Options for treatment

- + Steroid

 - + 2-3mg/kg/day or 50-60mg/m²/day prednisolone PO in dogs >25Kg

 - + 0.2-0.4mg/kg dexamethasone IV if PO not tolerated

- + Side effects include PU/PD/PP, iatrogenic hyperadrenocorticism, and diabetes and immunosuppression



Cyclosporin

- + Cyclosporin

 - + 5mg/kg PO BID

- + Side effects

 - + Vomiting, diarrhoea, anorexia, gingival hyperplasia, increased risk of malignancy. Risk of toxoplasmosis in cats



Mycophenolate mofetil

- + Mycophenolate mofetil
 - + 10mg/kg PO BID
- + Side effects
 - + GI upsets, bone marrow suppression



Azathioprine

- + Azathioprine NEVER IN CATS
 - + 2mg/kg or 50mg/m² PO SID
- + Side effects include bone marrow suppression, pancreatitis, hepatotoxicity.
- + Cats develop fatal leucopenia and thrombocytopenia
 - + Deficient in the enzyme thiopurine methyltransferase (TPMT), which is important for azathioprine metabolism

Non responsive patients

- + Repeat transfusions to buy time
- + Add in additional immunosuppressant
- + Splenectomy?
- + IVIG?



Splenectomy

- + Previous study investigating splenectomy for the management of dogs with IMHA
- + Of the 7 dogs with IMHA, splenectomy was part of a successful management protocol in 4 dogs (2 complete and 2 partial responses)

Bestwick JP, Skelly BJ, Swann JW, Glanemann B, Bexfield N, Gkoka Z, Walker DJ, Silvestrini P, Adamantos S, Seth M, Warland J. Splenectomy in the management of primary immune-mediated hemolytic anemia and primary immune-mediated thrombocytopenia in dogs. *J Vet Intern Med.* 2022 Jul;36(4):1267-1280. doi: 10.1111/jvim.16469. Epub 2022 Jul 7. PMID: 35801263; PMCID: PMC9308443.

IVIG

- + Previous study investigating the IV use of the use of high-dose IgM-enriched hIVIG (Pentaglobin) in dogs with primary immune-mediated haemolytic anaemia
- + Ten of 11 dogs from the treatment group and 2 of 3 dogs from the control group achieved remission and survived until hospital discharge.
- + Survival and time to remission were not significantly different between groups.
- + The volume of packed red blood cells transfused, normalized for body weight, was not significantly different between groups.
- + Potential adverse reactions to Pentaglobin occurred in 2 dogs

Bestwick JP, Sharman M, Whitley NT, Kisielewicz C, Skelly BJ, Tappin S, Kellett-Gregory L, Seth M. The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia. *J Vet Intern Med.* 2022 Jan;36(1):78-85. doi: 10.1111/jvim.16315. Epub 2021 Nov 15. PMID: 34779044; PMCID: PMC8783326.

Thromboembolism

- + Major cause of mortality in dogs
- + IMHA patients have evidence of hypercoagulability and platelet activation

Conway EA, Evans NP, Ridyard AE. Urinary 11-dehydrothromboxane B₂ concentrations in 20 dogs with primary immune-mediated hemolytic anemia. *J Vet Intern Med.* 2022 Jan;36(1):86-96. doi: 10.1111/jvim.16322. Epub 2021 Dec 3. PMID: 34859495; PMCID: PMC8783321.

Thromboprophylaxis

- + Aspirin (0.5mg/g/day) or clopidogrel (1.1-4mg/kg/day) most commonly used
- + Easily available and no need for intensive monitoring
- + Aspirin COX inhibitor. Thromboxane A2 is produced by platelet in COX1 dependant manner. Thromboxane is a potent platelet agonist.
- + Clopidogrel irreversibly inhibits platelet P2Y12 ADP receptor. ADP is potent activator of platelets.


Clopidogrel use

- + Previous study investigating use of clopidogrel alone or in combination with ultra low dose aspirin in dogs with primary immune-mediated haemolytic anaemia
- + There was no identifiable adverse reaction, evidence of hemorrhage, or increase in transfusion requirements associated with CL therapy, either alone or combined with ULDA, compared with ULDA alone.
- + There was no significant difference between treatment groups with respect to survival to discharge and at 90 days.

Mellett AM, Nakamura RK, Bianco D. A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia. *J Vet Intern Med.* 2011 Jan-Feb;25(1):71-5. doi: 10.1111/j.1939-1676.2010.0656.x. Epub 2010 Dec 13. PMID: 21155892.


Poppy

- + 3yr FN English Springer Spaniel
- + Acute history of lethargy and pigmenturia
- + No known toxin exposure
- + No travel history
- + No current medications



Physical examination

- + Very lethargic
- + HR 180 with poor pulses
- + RR 50 with normal lung sounds
- + Pale mucous membranes
- + Abdominal palpation normal



Stabilisation/Initial investigations























- + Supplemental oxygen
- + 10ml/kg bolus of Compound Sodium lactate
- + Haematology
- + Serum biochemistry
- + Urinalysis



Haematology results Day 1

🚫 🚫	RBC	1.17	5.39 - 8.70 x10 ¹² /L	
🚫 🚫	Haematocrit	0.109	0.383 - 0.565 L/L	
🚫 🚫	Haemoglobin	40	134 - 207 g/L	
🚫 🚫	MCV	93.2	59.0 - 76.0 fL	
🚫 🚫	MCH	34.2	21.9 - 26.1 pg	
🚫 🚫	MCHC	367	326 - 392 g/L	
🚫 🚫	Reticulocytes	a. 180.2	<= 110.0 K/μL	
🚫 🚫	Reticulocyte Haemoglobin	19.8	24.5 - 31.8 pg	
🚫 🚫	WBC	17.2	4.9 - 17.6 x10 ⁹ /L	
🚫	% Neutrophils	73.0	%	
🚫	% Bands	8.0	%	
🚫	% Metamyelocytes	2.0	%	
🚫	% Lymphocytes	12.0	%	
🚫	% Monocytes	5.0	%	
🚫	% Eosinophils	0.0	%	
🚫	% Basophils	0.0	%	

Haematology results

 	Neutrophils	12.56	2.94 - 12.67 x10 ⁹ /L	
 	Bands	1.38	0.00 - 0.17 x10 ⁹ /L	
	Metamyelocytes	0.34	x10 ⁹ /L	
 	Lymphocytes	2.06	1.06 - 4.95 x10 ⁹ /L	
 	Monocytes	0.86	0.13 - 1.15 x10 ⁹ /L	
 	Eosinophils	0.00	0.07 - 1.49 x10 ⁹ /L	
 	Basophils	0.00	0.00 - 0.10 x10 ⁹ /L	
	Nucleated RBC (Absolute)	3.10	10 ⁹ /L	
 	Platelets	666	143 - 448 x10 ⁹ /L	

Blood smear analysis




































Blood Film Evaluation

Red cells show marked anisocytosis and polychromasia.
Ghost cells, spherocytes and auto-agglutination present.
Metarubricytes noted.
Band cells present with few metamyelocytes. A few neutrophils show Dohle bodies.
Platelet count falsely raised due to the presence of cell debris.
Estimation of free platelets (>8 platelets seen per HPF) suggesting platelet numbers are normal.
Manual Differential performed by a haematological technician to replace or complete automated results.

Coombs' (37° C)

POSITIVE

Biochemistry results

  Glucose	6.08	3.89 - 7.95 mmol/L	
  IDEXX SDMA	a. 6	0 - 14 µg/dL	
  Creatinine	61	44 - 159 µmol/L	
  Urea	5.3	2.5 - 9.6 mmol/L	
 BUN: Creatinine Ratio	22		
  Phosphorus	0.92	0.81 - 2.20 mmol/L	
  Calcium	2.22	1.98 - 3.00 mmol/L	
  Total Protein	68	52 - 82 g/L	
  Albumin	30	22 - 39 g/L	
  Globulin	38	25 - 45 g/L	
 Albumin: Globulin Ratio	0.8		
  ALT	43	10 - 125 U/L	
  ALP	95	23 - 212 U/L	

Biochemistry results

GGT	0	0 - 11 U/L	
Bilirubin - Total	15	0 - 15 µmol/L	
Cholesterol	6.35	2.84 - 8.26 mmol/L	
Amylase	544	500 - 1,500 U/L	
Lipase	424	200 - 1,800 U/L	


Urinalysis

- + Port wine colour
- + Spun and no cell pellet-
supernatant remained
pigmented

































Initial Treatment

- + 0.3mg/kg dexamethasone IV
- + Clopidogrel 75mg PO SID
- + Blood type
- + DEA 1.1 negative
- + Packed red blood cell transfusion administered



Haematology results Day 2

  RBC	2.37	5.39 - 8.70 x10 ¹² /L	
  Haematocrit	0.199	0.383 - 0.565 L/L	
  Haemoglobin	73	134 - 207 g/L	
  MCV	84.0	59.0 - 76.0 fL	
  MCH	30.8	21.9 - 26.1 pg	
  MCHC	367	326 - 392 g/L	
 Reticulocytes	e. 164.5	<= 110.0 K/ μ L	
  Reticulocyte Haemoglobin	25.3	24.5 - 31.8 pg	
  WBC	21.5	4.9 - 17.6 x10 ⁹ /L	
 % Neutrophils	78.0	%	
 % Bands	13.0	%	
 % Lymphocytes	6.0	%	
 % Monocytes	2.0	%	
 % Eosinophils	1.0	%	
 % Basophils	0.0	%	

Blood smear analysis

Blood Film Evaluation

Marked spherocytosis, mild polychromasia and moderate numbers of metarubricytes.

Moderate numbers of ghost cells and mild agglutination.

Band cells present.

Manual Differential performed by a haematological technician to replace or complete automated results.

Treatment

- + Prednisolone 50mg PO SID (2mg/kg SID)
 - + Mycophenolate 250mg PO BID (10mg/kg BID)
 - + 75mg clopidogrel PO SID
 - + Rest and TLC
-
- + Discharged Day 5 when PCV 25% and hemodynamically stable

Haematology results- day 10

■ ■	📉	RBC	5.03	5.39 - 8.70 x10 ¹² /L	
■ ■	📉	Haematocrit	0.355	0.383 - 0.565 L/L	
■ ■	📉	Haemoglobin	117	134 - 207 g/L	
■ ■	📉	MCV	70.6	59.0 - 76.0 fL	
■ ■	📉	MCH	23.3	21.9 - 26.1 pg	
■ ■	📉	MCHC	330	326 - 392 g/L	
■ ■		Reticulocytes	a. 49.8	<= 110.0 K/μL	
■ ■	📉	Reticulocyte Haemoglobin	28.1	24.5 - 31.8 pg	
■ ■	📈	WBC	6.0	4.9 - 17.6 x10 ⁹ /L	
■ ■		% Neutrophils	56.0	%	
■ ■		% Bands	2.0	%	
■ ■		% Lymphocytes	32.0	%	
■ ■		% Monocytes	10.0	%	
■ ■		% Eosinophils	0.0	%	
■ ■		% Basophils	0.0	%	


Blood smear analysis

Blood Film Evaluation

No morphological abnormalities detected in red blood cells.
No abnormal white cells seen.
Estimation of free platelets (>8 platelets seen per HPF) suggesting platelet numbers are normal.
However, platelet clumps are seen. Platelet count and estimate should be considered the minimum value.
Manual differential performed by a haematological technician to replace or complete automated results.

Outcome

- + Responded well to treatment
- + Prednisolone tapered by 25% every 3 weeks, with haematology/smear performed prior to each tapering
- + Mycophenolate stopped after 2 months
- + No signs of recurrence



Maisie

- + 10m FN British Shorthair
- + Reduced appetite for past 2 weeks
- + Hiding under bed for last 3 days
- + Indoor only
- + Up to date with vaccinations
- + No current medications
- + No travel history



Physical examination






















- + Very flat
- + Icteric skin and mucous membranes/conjunctiva
- + HR 240 with poor pulses
- + RR 24
- + Abdominal palpation – fluid thrill



Haematology results

■ ■	🦋	RBC	1.21	7.12 - 11.46 x10 ¹² /L	
■ ■	🦋	Haematocrit	0.079	0.282 - 0.527 L/L	
■ ■	🦋	Haemoglobin	23	103 - 162 g/L	
■ ■	🦋	MCV	65.3	39.0 - 56.0 fL	
■ ■	🦋	MCH	19.0	12.6 - 16.5 pg	
■ ■	🦋	MCHC	291	285 - 378 g/L	
■ ■		Reticulocytes	a. 432.3	<= 50.0 K/μL	
■ ■	🦋	Reticulocyte Haemoglobin	19.1	15.3 - 22.9 pg	
■ ■	🦋	WBC	26.5	3.9 - 19.0 x10 ⁹ /L	
■ ■		% Neutrophils	74.0	%	
■ ■		% Bands	9.0	%	
■ ■		% Lymphocytes	9.0	%	
■ ■		% Monocytes	8.0	%	
■ ■		% Eosinophils	0.0	%	
■ ■		% Basophils	0.0	%	

Haematology results

 	Neutrophils	19.61	2.62 - 15.17 x10 ⁹ /L	
 	Bands	2.39	0.00 - 0.30 x10 ⁹ /L	
 	Lymphocytes	2.39	0.85 - 5.85 x10 ⁹ /L	
 	Monocytes	2.12	0.04 - 0.53 x10 ⁹ /L	
 	Eosinophils	0.00	0.09 - 2.18 x10 ⁹ /L	
 	Basophils	0.00	0.00 - 0.10 x10 ⁹ /L	
	Nucleated RBC (Absolute)	5.04	10 ⁹ /L	
	Nucleated RBC	b. 19	per 100wbc	
 	Platelets	~		

Blood smear analysis

Blood Film Evaluation

Red cells show marked anisocytosis and polychromasia.

Auto-agglutination present. Many ghost cells and metarubricytes noted.







Band cells seen.

Platelet count invalidated due to the presence of cell debris.

Estimation of free platelets (>8 platelets seen per HPF) suggesting platelet numbers are normal.


Manual Differential performed by a haematological technician to replace or complete automated results.

Biochemistry results


Glucose	7.64	3.95 - 8.84 mmol/L	
Creatinine	94	71 - 212 µmol/L	
Urea	20.3	5.7 - 12.9 mmol/L	
BUN: Creatinine Ratio	54		
Phosphorus	2.29	1.00 - 2.42 mmol/L	
Calcium	2.15	1.95 - 2.83 mmol/L	
Total Protein	96.2	60.0 - 80.0 g/L	
Albumin	19.4	25.0 - 45.0 g/L	
Globulin	76.8	25.0 - 45.0 g/L	
Albumin: Globulin Ratio	0.25	0.60 - 1.50	
ALT	226	12 - 130 U/L	
ALP	<10	14 - 111 U/L	
GGT	0	0 - 4 U/L	
Bilirubin - Total	39	0 - 15 µmol/L	
Cholesterol	2.53	1.68 - 5.81 mmol/L	

Stabilisation

- + Suspect secondary IMHA
- + 0.3mg/kg dexamethasone
- + Blood type A
- + Whole blood transfusion



Further investigations - Serum Protein Electrophoresis



FELINE PROTEIN ELECTROPHORESIS - AGAROSE GEL

Fraction	g/L	Interpretative guidelines
Albumin (spe)	18.29	(25.0 - 45.0)
Alpha 1	2.18	(2.0 - 5.0)
Alpha 2	13.50	(8.0 - 11.0)
Beta	8.83	(6.0 - 11.0)
Gamma	53.39	(12.0 - 32.0)

DESCRIPTION:

Albumin is similarly reduced on the trace. There is a mild increase in alpha 2 globulins and a marked polyclonal increase in gamma globulins. Other globulin fractions are normal.

Further testing

Coombs' (37° C)	a. Positive
Mycoplasma haemofelis RealPCR	NEGATIVE
Candidatus Mycoplasma haemominutum RealPCR	NEGATIVE
Candidatus Mycoplasma turicensis RealPCR	NEGATIVE

Further testing

FeLV Antigen by ELISA	NEGATIVE
FIV Antibody by ELISA	NEGATIVE



Alpha 1 Acid Glycoprotein


2.8

0.0 - 1.5 g/L



Abdominal ultrasound

- + Moderate ascites
 - + Abdominocentesis – yellow, straw-coloured fluid obtained
- + Moderate mesenteric lymphadenopathy
- + Rest unremarkable




Analysis of abdominal effusion

Site:	ASC
Appearance	4ml, Viscous, Clear, Pale Yellow fluid, Containing Particles
Protein	80 g/L
Viscosity	-DNR
RBC	less than 15,000
Nucleated Cells	17,090 /uL
Cell Count Method	Procyte
Clinical Pathologist's Report	INTERPRETATION: Exudate
Site:	ASCITIC FLUID & SWAB:
Aerobic Culture - Fluid	No bacterial growth.
Anaerobic Culture - Fluid	No anaerobes isolated
Feline Coronavirus RealPCR	a. POSITIVE

Investigations and treatment

- + Secondary IMHA due to FIP
- + Blood transfusion increased PCV to 13% and improved cardiovascular parameters
- + Remdesivir IV given alongside dexamethasone IV



STANDARD ARTICLE |  Open Access |  

Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524

Jodie Green , Harriet Syme, Sarah Tayler

First published: 04 July 2023 | <https://doi.org/10.1111/jvim.16804>











Journal of Feline Medicine and Surgery
Volume 25, Issue 8, August 2023
© The Author(s) 2023, Article Reuse Guidelines
<https://doi.org/10.1177/1098612X231183250>

Sage Journals

Original Article



Long-term follow-up of cats in complete remission after treatment of feline infectious peritonitis with oral GS-441524

Katharina Zwicklbauer ¹, Daniela Krentz ¹, Michèle Bergmann ¹, Sandra Felten¹, Roswitha Dorsch ¹, Andrea Fischer¹, Regina Hofmann-Lehmann ², Marina L Meli ², Andrea M Spiri ², Martin Alberer³, Laura Kolberg ³, Kaspar Matiassek⁴, Yury Zablotski ¹, Ulrich von Both ^{3,5}, and Katrin Hartmann¹










Journal of Feline Medicine and Surgery
Volume 25, Issue 9, September 2023
© The Author(s) 2023, Article Reuse Guidelines
<https://doi.org/10.1177/1098612X231194460>

Sage Journals

Original Article



Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020–2022)

Samantha S Taylor ^{1,2,3}, Sally Coggins⁴, Emi N Barker ^{5,6}, Daniëlle Gunn-Moore⁷, Kamalan Jeevaratnam³, Jacqueline M Norris⁴, David Hughes⁸, Emily Stacey ⁹, Laura MacFarlane¹⁰, Carolyn O'Brien¹¹, Rachel Korman¹², Gerard McLauchlan ¹³, Xavier Salord Torres¹⁴, Aimee Taylor⁵, Jos Bongers¹⁵, Laura Espada Castro¹⁵, Max Foreman ¹⁶, James McMurrough¹⁷, Bethany Thomas ¹⁷, Emilie Royaux¹⁸, Isabel Calvo Saiz¹⁹, Guido Bertoldi¹⁹, Caroline Harlos²⁰, Megan Work ²¹, Cameron Prior ²¹, Stephanie Sorrell ²², Richard Malik⁴, and Séverine Tasker^{2,6}

Outcome

- + Hospitalised for 7 days. PCV increased to 18%.
- + Continued on 10mg/kg remdesivir IV for 4 days then 10mg/kg SQ for 3 days.
- + Continued IV dexamethasone in hospital
- + Transitioned to 12mg/kg GS-441524 for 84 days and oral prednisolone
- + Prednisolone tapered and stopped over 3 weeks
- + Blood work normalised and ascites resolved
- + In remission



Summary

- + IMHA can be a life-threatening emergency.
- + Secondary IMHA is more common in cats.
- + Blood transfusions can be life-saving.
- + Outcomes can be favourable and remission can be achieved.



Questions?

